A detailed history of State Street Corp transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 39,530 shares of CYTH stock, worth $48,226. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,530
Previous 39,525 0.01%
Holding current value
$48,226
Previous $62,000 12.9%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.39 - $1.9 $6 - $9
5 Added 0.01%
39,530 $54,000
Q4 2023

Feb 14, 2024

BUY
$0.93 - $1.88 $6,812 - $13,771
7,325 Added 22.75%
39,525 $62,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $1.88 $4,914 - $7,332
3,900 Added 13.78%
32,200 $45,000
Q4 2021

Feb 14, 2022

SELL
$3.47 - $7.34 $4,511 - $9,542
-1,300 Reduced 4.39%
28,300 $106,000
Q3 2021

Nov 15, 2021

SELL
$6.21 - $10.04 $93,771 - $151,604
-15,100 Reduced 33.78%
29,600 $200,000
Q2 2021

Aug 16, 2021

BUY
$6.58 - $10.85 $294,126 - $484,995
44,700 New
44,700 $457,000

Others Institutions Holding CYTH

About Cyclo Therapeutics, Inc.


  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $10.3M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.